口腔黏膜下纤维性变临床诊治的研究进展

doi:10.13701/j.cnki.kqyxyj.2022.08.001

口腔医学研究 ›› 2022, Vol. 38 ›› Issue (8): 705-709.DOI: 10.13701/j.cnki.kqyxyj.2022.08.001

• 特约述评 • 下一篇

口腔黏膜下纤维性变临床诊治的研究进展

唐瞻贵^*, 成雨熹

中南大学湘雅口腔医院口腔颌面外科湖南长沙 410078

收稿日期:2022-05-25 出版日期:2022-08-28 发布日期:2022-08-24
作者简介:唐瞻贵,男,中国共产党党员,医学博士,博士后,一级主任医师,二级教授,湘雅名医,博士生导师,享受国务院政府特殊津贴。现任中南大学湘雅口腔医院院长,口腔医学院院长,口腔医学研究所所长。中国整形美容协会口腔整形美容分会副会长,中国抗癌协会口腔颌面肿瘤整合医学专业委员会副主委,中国牙病防治基金会理事会理事,湖南省口腔健康促进会会长,湖南省口腔医学会副会长。《口腔医学研究》副主编,《中华口腔医学杂志》、《中国口腔颌面外科杂志》等10余部杂志编委。主持国家自然科学基金等国家级课题6项,国家博士点基金、省科技厅重点项目等省部级项目20余项,获湖南省科技进步三等奖2项,湖南医学科技二等奖2项,教育部成果1项。主编、参编著作10余部。主持《口腔疣状癌临床诊治全国专家共识》及《口腔医学中恶性高热临床诊治中国专家共识》的讨论和撰写。

Advancements of Clinical and Basic Research in Oral Submucous Fibrosis

TANG Zhangui^*, CHENG Yuxi

Department of Oral and Maxillofacial Surgery, Xiangya Stomatological Hospital, Central South University, Changsha 410078, China

Received:2022-05-25 Online:2022-08-28 Published:2022-08-24

摘要/Abstract

摘要： 口腔黏膜下纤维性变(oral submucous fibrosis,OSF) 是一种胶原沉积疾病,其特征是产生疤痕和组织纤维化,会严重影响患者的口腔功能和生活质量。根据世界卫生组织(WHO)的统计,全球有超过500万OSF患者,恶性转化率为1.5%~15%,因此WHO也将其列入口腔潜在恶性疾患的范畴。现对OSF的临床及基础研究进展进行总结,旨在了解该病发病规律及为临床早期防治提供参考。

关键词: 口腔黏膜下纤维性变, 诊断, 治疗

Abstract: Oral submucosal fibrosis (OSF) is a collagen deposition disease characterized by scarring and tissue fibrosis, which can severely affect the oral function and quality of life of patients. According to the World Health Organization (WHO), there are more than 5 million OSF patients worldwide, with malignant transformation rates ranging from 1.5%-15%. Thus WHO has included it in the category of potentially malignant disorders of the oral cavity. The clinical and basic research progress of OSF is reviewed in this paper, with aim to provide a reference for understanding the pathogenesis of the disease and its early clinical prevention and treatment.

Key words: oral submucosal fibrosis, diagnosis, treatment

唐瞻贵, 成雨熹. 口腔黏膜下纤维性变临床诊治的研究进展[J]. 口腔医学研究, 2022, 38(8): 705-709.

TANG Zhangui, CHENG Yuxi. Advancements of Clinical and Basic Research in Oral Submucous Fibrosis[J]. Journal of Oral Science Research, 2022, 38(8): 705-709.

参考文献

[1] Liu B, Shen M, Xiong J, et al. Synergistic effects of betel quid chewing, tobacco use (in the form of cigarette smoking), and alcohol consumption on the risk of malignant transformation of oral submucous fibrosis (OSF): a case-control study in Hunan Province, China [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 120(3):337-345.
[2] Yadav A, Kumar L, Misra N, et al. Estimation of serum zinc, copper, and iron in the patients of oral submucous fibrosis [J]. Natl J Maxillofac Surg, 2015, 6(2):190-193.
[3] Abidullah M, Gaddikeri K, Anjum B, et al. Evaluation of hematological profile in oral submucous fibrosis [J]. Cureus, 2022, 14(2):e21926.
[4] Choudhury Y, Sharan RN. Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN) [J]. Environ Toxicol Pharmacol, 2011, 31(1):57-69.
[5] Moutasim KA, Jenei V, Sapienza K, et al. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis [J]. J Pathol, 2011, 223(3):366-377.
[6] Ayinampudi BK, Narsimhan M. Salivary copper and zinc levels in oral pre-malignant and malignant lesions [J]. J Oral Maxillofac Pathol, 2012, 16(2):178-182.
[7] Jayasooriya PR, Nadeeka Jayasinghe KA, Mudiyanselage Tilakaratne W. Relationship between thickness of fibrosis and epithelial dysplasia in oral submucous fibrosis [J]. J Investig Clin Dent, 2011, 2(3): 171-175.
[8] Ho YC, Yang SF, Lee SS, et al. Regulation of hypoxia-inducible factor-1α in human buccal mucosal fibroblasts stimulated with arecoline [J]. J Formos Med Assoc, 2017,116(6): 484-487.
[9] Chakraborti S, Paul RR, Pal M, et al. Collagen deposition correlates with loss of E-cadherin and increased p63 expression in dysplastic conditions of oral submucous fibrosis [J]. Med Mol Morphol, 2022, 55(1):20-26.
[10] Nag R, Paul RR, Pal M, et al. Epithelial distribution of E-cadherin, p63, and mitotic figures in apotome images to determine the oncogenic potentiality of oral submucous fibrosis [J]. Microsc Microanal, 2020, 26(6):1198-1210.
[11] Desai RS, Mamatha GS, Khatri MJ, et al. Immunohistochemical expression of CD34 for characterization and quantification of mucosal vasculature and its probable role in malignant transformation of atrophic epithelium in oral submucous fibrosis [J]. Oral Oncol, 2010, 46(7):553-558.
[12] Sharma E, Tyagi N, Gupta V, et al. Role of angiogenesis in oral submucous fibrosis using vascular endothelial growth factor and CD34: An immunohistochemical study [J]. Indian J Dent Res, 2019, 30(5):755-762.
[13] Sun Y, Wang T, Wen QT, et al. VEGF gene transfection restores the angiogenesis of oral submucous fibrosis in mice [J]. Ann Transl Med, 2021, 9(11):930.
[14] Shen YW, Shih YH, Fuh LJ, et al. Oral submucous fibrosis: A review on biomarkers, pathogenic mechanisms, and treatments [J]. Int J Mol Sci, 2020, 21(19):7231.
[15] 唐瞻贵.口腔黏膜下纤维化回顾与展望[C]//.2019年中华口腔医学会口腔颌面外科专业委员会第十三次全国口腔颌面-头颈肿瘤内科学术会议论文汇编.2019:35-36+18.
[16] 蔡鑫嘉,姚志刚,刘桂,等.口腔黏膜下纤维化:674例临床病理研究[C]//.2019年中华口腔医学会口腔病理学专业委员会第十三次全国口腔病理学术会议论文汇编.2019:69.
[17] Bhatt P, Manjunath M, Khakhla D, et al. Assessment and correlation between functional and histological staging of oral submucous fibrosis: A clinicohistopathologic study [J]. Natl J Maxillofac Surg, 2019, 10(1):27-32.
[18] Biradar SB, Munde AD, Biradar BC, et al. Oral submucous fibrosis: A clinico-histopathological correlational study [J]. J Cancer Res Ther, 2018, 14(3):597-603.
[19] Tilakaratne WM, Ekanayaka RP, Herath M, et al. Intralesional corticosteroids as a treatment for restricted mouth opening in oral submucous fibrosis [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(2):224-231.
[20] Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis [J]. Indian J Dent Res, 2006, 17(4):190-198.
[21] Liu J, Chen F, Wei Z, et al. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis [J]. Oral Dis, 2018, 24(5):706-716.
[22] Kumar A, Bagewadi A, Keluskar V, et al. Efficacy of lycopene in the management of oral submucous fibrosis [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 103(2):207-213.
[23] Gupta S, Jawanda MK, Arora V, et al. Role of lycopene in preventing oral diseases as a nonsurgical aid of treatment [J]. Int J Prev Med, 2015, 6:70.
[24] Rajesh Kashyap R, Shanker Kashyap R. Herbal derivatives in the management of mouth opening in oral submucous fibrosis-A network meta-analysis [J]. Oral Dis, 2021, 27(7):1606-1615.
[25] Borle RM, Borle SR. Management of oral submucous fibrosis: a conservative approach [J]. J Oral Maxillofac Surg, 1991, 49(8):788-791.
[26] James L, Shetty A, Rishi D, et al. Management of oral submucous fibrosis with injection of hyaluronidase and dexamethasone in grade Ⅲ oral submucous fibrosis: A retrospective study [J]. J Int Oral Health, 2015, 7(8): 82-85.
[27] 杨博,唐瞻贵.丹参联合醋酸曲安奈德注射液治疗口腔黏膜下纤维化的Meta分析[J].中成药,2018,40(10):2165-2169.
[28] 肖益彩,翦新春,郑廉,等.口腔黏膜下纤维性变病损黏膜下曲安奈德联合丹参酮液注射方法及疗效探讨[J].上海口腔医学,2017,26(2):188-192.
[29] Kalani A, Chaturvedi P. Curcumin-primed and curcumin-loaded exosomes: potential neural therapy [J]. Neural Regen Res, 2017, 12(2):205-206.
[30] Piyush P, Mahajan A, Singh K, et al. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized controlled trial [J]. Oral Dis, 2019, 25(1):73-79.
[31] Nerkar Rajbhoj A, Kulkarni TM, Shete A, et al. A comparative study to evaluate efficacy of curcumin and aloe vera gel along with oral physiotherapy in the management of oral submucous fibrosis: A randomized clinical trial [J]. Asian Pac J Cancer Prev, 2021, 22(S1):107-112.
[32] Li YH, Chang WC, Chiang TE, et al. Mouth-opening device as a treatment modality in trismus patients with head and neck cancer and oral submucous fibrosis: a prospective study [J]. Clin Oral Investig, 2019, 23(1):469-476.
[33] Gondivkar SM, Gadbail AR, Sarode SC, et al. Clinical efficacy of mouth exercising devices in oral submucous fibrosis: A systematic review [J]. J Oral Biol Craniofac Res, 2020, 10(4):315-320.
[34] Shadamarshan RA, Sharma R, Grewal R, et al. Use of the greater palatine pedicled flap for the surgical management of trismus in oral submucous fibrosis [J]. Br J Oral Maxillofac Surg, 2021, 59(8):888-893.

口腔黏膜下纤维性变临床诊治的研究进展

Advancements of Clinical and Basic Research in Oral Submucous Fibrosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王甲甲, 王绍义. 特立帕肽在药物性颌骨坏死中的治疗作用[J]. 口腔医学研究, 2022, 38(8): 718-721.
[2]	陈霞, 梁燕. 右上颌第二磨牙C型根管1例[J]. 口腔医学研究, 2022, 38(8): 789-791.
[3]	吴倩倩, 缪延宇, 郑治国. 多发牛牙症2年疗效观察1例[J]. 口腔医学研究, 2022, 38(8): 792-793.
[4]	程静, 宋光泰. 再生性牙髓治疗成功的影响因素分析[J]. 口腔医学研究, 2022, 38(7): 597-600.
[5]	雷尚雪, 但红霞. 光动力治疗增效研究新进展[J]. 口腔医学研究, 2022, 38(6): 497-500.
[6]	曾康瑞, 夏文薇. 非牙髓源性根尖周病鉴别诊断及治疗[J]. 口腔医学研究, 2022, 38(6): 505-508.
[7]	杨倩, 赖仁发, 刘湘宁. 基于GEO数据挖掘与网络药理学探讨活血化瘀方治疗口腔扁平苔藓的机制研究[J]. 口腔医学研究, 2022, 38(5): 465-470.
[8]	王聃, 崔健, 全鹤, 徐伟成. 上颌侧切牙牙骨质撕裂1例[J]. 口腔医学研究, 2022, 38(5): 482-483.
[9]	郭娇阳, 税桦桦. 结节病累及双侧腮腺组织1例[J]. 口腔医学研究, 2022, 38(4): 381-382.
[10]	樊牮, 许庆安. 隐裂牙综合征研究进展[J]. 口腔医学研究, 2022, 38(3): 223-225.
[11]	郝燕清, 唐蓉, 王金孟, 林梓桐. 2014~2019年根管治疗后移位型根折发生占比的CBCT回顾性研究[J]. 口腔医学研究, 2022, 38(2): 181-185.
[12]	薛媛, 李霞. 3D打印技术定位上颌第一磨牙钙化根管口的体外研究[J]. 口腔医学研究, 2021, 37(9): 814-819.
[13]	周伟, 汤雅, 李厚轩, 陈斌, 闫福华. 牙周牙髓联合病变患牙预后观察的回顾性研究[J]. 口腔医学研究, 2021, 37(9): 825-829.
[14]	米热阿依克孜·马木提, 江阿力·帕孜力别克, 赵莉, 鲁皓, 田士霖. 根管治疗对牙周源性牙周牙髓联合病变细菌谱的影响[J]. 口腔医学研究, 2021, 37(9): 830-834.
[15]	项乾峰, 陈丹艳, 蔡伊琳, 孟子堰, 王春, 董维理. 80例下前牙松牙固定术的长期疗效观察[J]. 口腔医学研究, 2021, 37(9): 835-839.